Compare NVTS & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVTS | OCUL |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2020 | 2014 |
| Metric | NVTS | OCUL |
|---|---|---|
| Price | $14.82 | $9.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $6.68 | ★ $23.56 |
| AVG Volume (30 Days) | ★ 28.8M | 3.2M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $45,916,000.00 | $1,990,000.00 |
| Revenue This Year | N/A | $7.93 |
| Revenue Next Year | $71.28 | $96.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 3.48 |
| 52 Week Low | $1.80 | $6.23 |
| 52 Week High | $19.79 | $16.44 |
| Indicator | NVTS | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 59.25 | 53.40 |
| Support Level | $7.05 | $8.36 |
| Resistance Level | $17.79 | $9.86 |
| Average True Range (ATR) | 1.60 | 0.50 |
| MACD | 0.58 | 0.07 |
| Stochastic Oscillator | 54.31 | 60.62 |
Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components. Geographically, the company operates in Hong Kong, China, Europe, the United States, Rest of Asia, and Others. The majority of revenue is generated from Hong Kong.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.